INSM News and Press, Insmed Inc. From 08/03/23

Insmed Reports Second-Quarter 2023 Financial Results and Provides Business Update PR Newswire -- ARIKAYCE ® (amikacin liposome inhalation suspension) Total Revenue of $77.2 Million for the Second Quarter of 2023 Reflects Highest Quarter of Sales Since Launch ...

2023-08-02 15:16:45 ET Insmed ( NASDAQ: INSM ) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open. The consensus EPS Estimate is -$1.12 and the consensus Revenue Estimate is $70.23M (+7.7% Y/Y). Over the last 1 year, INSM has bea...

Insmed to Host Second-Quarter 2023 Financial Results Conference Call on Thursday, August 3, 2023 PR Newswire BRIDGEWATER, N.J. , July 20, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the liv...

2023-07-05 15:06:02 ET Summary Spero is eligible to receive up to $525 million in development and sales milestone payments as well as royalties on net product sales under the agreement with GSK. In addition, Spero has two other assets that will soon be evaluated in proof-of-concep...

2023-06-08 08:15:46 ET Summary Insmed Incorporated showcases strong financial growth and a diverse product pipeline, making it an attractive investment opportunity in the biopharmaceutical industry. The company focuses on developing treatments for rare and severe lung diseases, wi...

Insmed To Present at the Goldman Sachs 44th Annual Global Healthcare Conference PR Newswire BRIDGEWATER, N.J. , June 7, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with...

Insmed Presents Range of New Study Findings at American Thoracic Society 2023 International Conference PR Newswire —Brensocatib Reduced Risk of Exacerbations Irrespective of Disease Severity in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE) in Phase 2 WILLOW S...

Insmed Unveils New Research Platforms and Capabilities at Investor and Analyst Event, "The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More" PR Newswire —Early-Stage Research Pillar Anticipated to Generate at Least Six Investigat...

2023-05-06 18:21:04 ET Insmed Incorporated (INSM) Q1 2023 Results Conference Call May 04, 2023 08:30 AM ET Company Participants Bryan Dunn - Head of Investor Relations Will Lewis - Chair and Chief Executive Officer Sara Bonstein - Chief Financial Officer Mart...

2023-05-05 15:00:33 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...